At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 561 enrolled
Drug / intervention
ALKS 3831 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia
In Brief
A Phase 3 clinical trial evaluating ALKS 3831 and Olanzapine for Schizophrenia. Completed, enrolled 561 participants across 54 sites in 2 countries.
Detailed Summary
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2016
Primary CompletionNov 2018
TodayJul 2026
First PostedFeb 29, 2016
Enrollment StartMar 2, 2016
Primary CompletionNov 7, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.3 years ago
Interventions
ALKS 3831drug
Daily dosing
Olanzapinedrug
Daily dosing